Ticker >

Laurus Labs share price

Laurus Labs Ltd.

NSE: LAURUSLABS BSE: 540222 SECTOR: Pharmaceuticals & Drugs  206k   1k   486

398.80
0 0
BSE: 23 Feb 04:01 PM

Price Summary

Today's High

₹ 404

Today's Low

₹ 397

52 Week High

₹ 444.5

52 Week Low

₹ 279.65

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

21493.96 Cr.

Enterprise Value

23173.64 Cr.

No. of Shares

53.9 Cr.

P/E

105.02

P/B

5.25

Face Value

₹ 2

Div. Yield

0.5 %

Book Value (TTM)

₹  75.99

CASH

1.7 Cr.

DEBT

1681.38 Cr.

Promoter Holding

27.19 %

EPS (TTM)

₹  3.8

Sales Growth

22.66%

ROE

20.48 %

ROCE

22.28%

Profit Growth

1.37 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 20 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year22.66%
3 Year27.32%
5 Year23.29%

Profit Growth

1 Year1.37%
3 Year41.74%
5 Year34.44%

ROE%

1 Year20.48%
3 Year29.15%
5 Year21.86%

ROCE %

1 Year22.28%
3 Year28.13%
5 Year21.4%

Debt/Equity

0.4157

Price to Cash Flow

24.38

Interest Cover Ratio

8.21640356897735

CFO/PAT (5 Yr. Avg.)

1.07360257142696

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 27.19 0.04
Sep 2023 27.2 0.04
Jun 2023 27.2 0.04
Mar 2023 27.2 0.04
Dec 2022 27.2 0.04
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 41.7357374393166% for the Past 3 years.
  • The company has shown a good revenue growth of 27.3197182489211% for the Past 3 years.
  • Company has been maintaining healthy ROE of 29.1508488478111% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.1324362590615% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 8.21640356897735.
  • The Company has been maintaining an effective average operating margins of 24.1465297401171% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 86.4437230354234 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.07360257142696.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 6.49335784384336.

 Limitations

  • The company is trading at a high EV/EBITDA of 30.5536.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 1500.7 1279.34 1107.65 1158.03 1132.19
Total Expenditure 1115.6 1026.9 979.77 977.52 961.81
Operating Profit 385.1 252.44 127.88 180.51 170.38
Other Income 2.98 5.94 6.71 5.9 10.72
Interest 39.26 41.03 33.47 37.8 37.56
Depreciation 78.48 80.55 83.87 85.4 86.84
Exceptional Items 0 0 0 0 0
Profit Before Tax 270.34 136.8 17.25 63.21 56.7
Tax 71.29 34.52 4.18 16.54 14.06
Profit After Tax 199.05 102.28 13.07 46.67 42.64
Adjusted EPS (Rs) 3.7 1.9 0.24 0.87 0.79

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 2236.15 2797.34 4768.72 4707.04 5773.45
Total Expenditure 1884.69 2227.11 3258.85 3421.84 4291.69
Operating Profit 351.46 570.23 1509.87 1285.2 1481.76
Other Income 16.13 5.81 27.32 21.55 15.95
Interest 85.83 87.71 65.92 95.86 145.7
Depreciation 160.53 183.85 196.64 235.48 300.58
Exceptional Items 0 0 0 0 0
Profit Before Tax 121.22 304.48 1274.63 975.41 1051.43
Tax 26.23 37.43 318.52 225.32 291.05
Net Profit 94.99 267.05 956.11 750.09 760.38
Adjusted EPS (Rs.) 1.79 5 17.82 13.96 14.12

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 106.44 106.91 107.32 107.47 107.73
Total Reserves 1484.46 1708.89 2604.92 3280.74 3949.09
Borrowings 258.66 165 382.64 549.67 565.49
Other N/C liabilities 40.43 52.08 178.68 236.55 229.33
Current liabilities 1379.44 1636.72 2696.26 2899.57 2844.09
Total Liabilities 3269.43 3669.6 5969.82 7074 7695.73
Assets
Net Block 1598.99 1694.18 1818.04 2186.23 2884.16
Capital WIP 107.15 66.53 324.17 755.03 357.06
Intangible WIP 0 0 0 0 0
Investments 58.32 58.32 318.89 361.72 384.12
Loans & Advances 24.03 39.42 91.84 69.82 132.84
Other N/C Assets 47.13 26.51 30.8 31.16 28.52
Current Assets 1433.81 1784.64 3386.08 3670.04 3909.03
Total Assets 3269.43 3669.6 5969.82 7074 7695.73
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 121.22 304.48 1274.63 975.41 1051.43
Adjustment 242.18 288.19 240.43 322.36 442.51
Changes in Assets & Liabilities -44.89 -208.54 -594.55 -308.46 -344.26
Tax Paid -25.34 -39.45 -226.06 -166.34 -268.13
Operating Cash Flow 293.17 344.68 694.45 822.97 881.55
Investing Cash Flow -256.58 -216.83 -899.68 -836.61 -735.27
Financing Cash Flow -36.93 -127.48 243.13 15.19 -185.19
Net Cash Flow -0.35 0.37 37.9 1.55 -38.91

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 27.20 27.20 27.20 27.20 27.19
chandrakanth chereddi 0.01 0.01 0.01 0.01 0.01
chava narasimha rao 0.02 0.02 0.02 0.02 0.02
chunduru venkata lakshman... 2.50 2.50 2.50 2.50 2.50
hymavathi vantaram 0.04 0.04 0.04 0.04 0.04
kamala kommana 0.02 0.02 0.02 0.02 0.02
krishnaveni vasireddi 0.04 0.04 0.04 0.04 0.04
m/s. leven holdings (repr... 1.24 1.24 1.24 1.24 1.24
m/s. nsn holdings (repres... 23.04 23.04 23.04 23.04 23.03
nagamani thokala 0.02 0.02 0.02 0.02 0.02
narasimha rao suryadevara... 0.03 0.03 0.03 0.03 0.03
rama suryadevara 0.03 0.03 0.03 0.03 0.03
sekhar babu chunduru 0.02 0.02 0.02 0.02 0.02
venkata ravi kumar vantar... 0.19 0.19 0.19 0.19 0.19
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 72.80 72.80 72.80 72.80 72.81
akash bhanshali 1.14 1.33 1.33 1.33 1.31
amansa holdings private l... 3.80 4.17 4.05 4.05 2.85
anukar projects private l... 3.25 3.25 3.25 3.25 3.24
barclays wealth trustees ... 1.84 1.83 1.67 1.35 1.31
kotak funds - india midca... - - - - 1.25
life insurance corporatio... 2.70 2.70 2.70 2.70 2.70
new world fund inc 5.29 5.29 5.39 5.49 6.45
smallcap world fund, inc - - 3.47 3.55 4.10
tata aia life insurance c... - - - 1.39 1.12
bandhan multi cap fund - - - 1.02 -
bandhan core equity fund - - 1.07 - -
small cap world fund inc 3.43 3.43 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Laurus Labs invests over Rs 99 crore in subsidiary19 Feb 2024, 12:13PM Laurus Labs informs about updates on acquisition17 Feb 2024, 3:14PM Laurus Labs submits analyst meet intimation13 Feb 2024, 3:56PM Laurus Labs enters into joint venture agreement with Krka29 Jan 2024, 12:41PM Laurus Labs - Quaterly Results24 Jan 2024, 3:28PM Laurus Labs - Quaterly Results24 Jan 2024, 3:28PM Laurus Labs - Quaterly Results24 Jan 2024, 3:28PM Laurus Labs informs about board meeting 17 Jan 2024, 3:22PM USFDA inspects Andhra Pradesh facility of Laurus Labs’ arm 13 Dec 2023, 10:41AM Laurus Labs informs about investor presentation25 Nov 2023, 11:53AM Laurus Labs informs about analyst meeting 22 Nov 2023, 12:28PM Laurus Labs acquires additional stake in Laurus Bio21 Nov 2023, 10:30AM Laurus Labs informs about update on acquisition of shares21 Nov 2023, 10:24AM Laurus Labs informs about un-audited financial results 20 Oct 2023, 4:55PM Laurus Labs reports 83% fall in Q2 consolidated net profit20 Oct 2023, 3:44PM Laurus Labs - Quaterly Results20 Oct 2023, 2:55PM Laurus Labs - Quaterly Results20 Oct 2023, 2:55PM Laurus Labs - Quaterly Results20 Oct 2023, 2:55PM Laurus Labs informs about investor meeting20 Sep 2023, 12:18PM Laurus Labs to acquire stake in Laurus Bio12 Sep 2023, 9:49AM Laurus Labs informs about analyst meet 10 Aug 2023, 10:25AM Laurus Labs reports 89% fall in Q1 consolidated net profit27 Jul 2023, 4:13PM Laurus Labs - Quaterly Results27 Jul 2023, 2:54PM Laurus Labs - Quaterly Results27 Jul 2023, 2:54PM Laurus Labs - Quaterly Results27 Jul 2023, 2:54PM Laurus Labs informs about earnings conference call21 Jul 2023, 12:39PM Laurus Labs informs about earnings conference call21 Jul 2023, 12:35PM Laurus Labs informs about scrutinizer's report15 Jul 2023, 11:49AM Laurus Labs informs about AGM21 Jun 2023, 5:01PM Laurus Labs informs about AGM and annual report 21 Jun 2023, 3:28PM Laurus Labs informs about analyst meet 20 Jun 2023, 10:08AM Laurus labs inks pact with IIT Kanpur19 Jun 2023, 12:15PM Laurus Labs gets EIR from USFDA for Andhra Pradesh manufacturing facility15 Jun 2023, 5:54PM Laurus Labs informs about disclosure 15 Jun 2023, 5:14PM Laurus Labs to acquire additional stake of 7.24% in ImmunoACT31 May 2023, 6:23PM Laurus Labs informs about secretarial compliance report24 May 2023, 12:15PM Laurus Labs informs about updates9 May 2023, 2:30PM Laurus Labs gets USFDA’s tentative approval for Oral Dispersible Film Dolutegravir2 May 2023, 5:52PM Laurus Labs reports 54% fall in Q4 consolidated net profit28 Apr 2023, 12:38PM Laurus Labs - Quaterly Results27 Apr 2023, 3:01PM Laurus Labs - Quaterly Results27 Apr 2023, 3:01PM Laurus Labs - Quaterly Results27 Apr 2023, 3:01PM Laurus Labs informs about closure of trading window31 Mar 2023, 12:13PM Laurus Labs informs about analyst meeting 13 Mar 2023, 4:59PM Laurus Labs informs about disclosure10 Feb 2023, 5:22PM Laurus Labs informs about transcript of earnings call 4 Feb 2023, 10:25AM Laurus Labs reports 31% rise in Q3 consolidated net profit 30 Jan 2023, 4:00PM Laurus Labs - Quaterly Results30 Jan 2023, 11:53AM Laurus Labs - Quaterly Results30 Jan 2023, 11:53AM Laurus Labs - Quaterly Results30 Jan 2023, 11:53AM

Laurus Labs Stock Price Analysis and Quick Research Report. Is Laurus Labs an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Laurus Labs and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Laurus Labs cash from the operating activity was Rs 881.55 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Laurus Labs has a Debt to Equity ratio of 0.4157 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Laurus Labs , the EPS growth was 1.12686347973724 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Laurus Labs has OPM of 25.6650702786029 % which is a good sign for profitability.
     
  • ROE: Laurus Labs have a healthy ROE of 20.4848164831139 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Laurus Labs is Rs 398.55. One can use valuation calculators of ticker to know if Laurus Labs share price is undervalued or overvalued.
Last Updated on:
Brief about Laurus Labs

Laurus Labs Ltd Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Laurus Labs Ltd. is a renowned pharmaceutical company that specializes in the research, development, and manufacturing of generic APIs (Active Pharmaceutical Ingredients) and research and development (R&D) services to the global pharmaceutical industry. Here, we will delve into Laurus Labs Ltd.'s various aspects, including its share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders. This analysis is tailored specifically for long-term stock investors seeking comprehensive stock evaluation. Additionally, we will highlight the use of Ticker pre-built screening tools that support fair value calculation through DCF (Discounted Cash Flow) Analysis, BVPS (Book Value per Share) Analysis, Earnings Multiple Approach, and DuPont Analysis.

Laurus Labs Ltd Share Price

Laurus Labs Ltd.'s share price is a key parameter for investors interested in long-term stock analysis. It is crucial to monitor and track the company's share price, which can be done through our trading platform. Laurus Labs Ltd. is traded on various stock exchanges, such as the BSE (Bombay Stock Exchange) and NSE (National Stock Exchange), and investing in its shares can be done through these exchanges.

Laurus Labs Ltd Balance Sheet

The balance sheet is an essential financial statement that provides insights into Laurus Labs Ltd.'s assets, liabilities, and shareholder's equity at a particular point in time. It serves as a snapshot of the company's financial health and stability and is of utmost importance to long-term investors. Ticker innovative screening tools enable investors to calculate fair value using DCF Analysis, BVPS Analysis, Earnings Multiple Approach, and DuPont Analysis, thereby empowering them to make informed investment decisions.

Laurus Labs Ltd Annual Report

Laurus Labs Ltd.'s annual report is a comprehensive document that offers details about the company's performance, strategies, and governance in the preceding year. Ticker simplifies access to these annual reports, making them easily downloadable for investors' convenience. Studying the annual reports is crucial as it provides insights into the company's business model, growth trajectory, and future plans, enabling investors to gain a deeper understanding of Laurus Labs Ltd.

Laurus Labs Ltd Dividend

As a reputable company, Laurus Labs Ltd. values its shareholders and regularly distributes dividends to them. Dividends are a portion of the company's profits paid out to shareholders as a return on their investment. At our platform, investors can explore the company's dividend history and stay updated on the latest dividend announcements.

Laurus Labs Ltd Quarterly Results

To analyze Laurus Labs Ltd.'s financial performance over specific periods, it is necessary to review the company's quarterly results. Ticker offers a range of tools and resources to facilitate this analysis. Investors can access quarterly reports, utilize analytical tools, and employ pre-built screening tools to assess the company's growth trends, profitability, and overall financial stability.

Laurus Labs Ltd Stock Price

Monitoring stock prices is pivotal for investors aiming to buy or sell shares of Laurus Labs Ltd. Ticker platform delivers real-time stock price data, ensuring that investors have access to the latest information to make informed decisions. Along with the stock price, investors can closely track its fluctuations, historical trends, and trading volumes to evaluate the stock's performance.

Laurus Labs Ltd Price Chart

Price charts provide graphical representations of a stock's historical price movements, helping investors identify trends and patterns. Ticker offers comprehensive price charts of Laurus Labs Ltd., allowing investors to visualize the stock's performance over time.

Laurus Labs Ltd News

Keeping abreast of the latest news about Laurus Labs Ltd. is vital for long-term investors. Our platform provides up-to-date news, including market changes, corporate announcements, industry developments, and other relevant events that may impact the stock market. Investors can access these news updates to stay informed and make well-informed investment decisions.

Laurus Labs Ltd Concall Transcripts

Conference call transcripts provide valuable insights into Laurus Labs Ltd.'s management discussions regarding financial results, operational strategies, and future plans. By offering access to concall transcripts, our platform ensures that investors have access to first-hand information about the company's direction and future prospects.

Laurus Labs Ltd Investor Presentations

Laurus Labs Ltd. presents its corporate strategies, financial performance, and future projections through investor presentations. These presentations offer a glimpse into the company's growth plans, market positioning, and operational strategies. Ticker provides the facility to download these presentations, enabling investors to make well-informed decisions based on a comprehensive understanding of the company's objectives.

Laurus Labs Ltd Promoters

Promoters play a pivotal role in the success of Laurus Labs Ltd. They are individuals or entities responsible for starting the company, raising capital, and maintaining management control. Understanding the promoters' vision, strategies, and plans for the company's future is integral to evaluating the investment potential of Laurus Labs Ltd.

Laurus Labs Ltd Shareholders

Shareholders are critical stakeholders in any company. They provide the necessary capital and possess ownership through shares. Identifying the major shareholders of Laurus Labs Ltd., along with their respective stakes and voting power, is indispensable for assessing the company's governance structure and overall stability.

Read More
X